Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0022104 (
irritable bowel syndrome
)
8,033
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A highly sensitive radioimmunoassay system for plasma
vasoactive intestinal peptide (VIP)
was developed to examine the effect of intraduodenal infusion of HCl or fat on the plasma VIP levels in healthy subjects, and the effect of intramuscular injection of neostigmine in patients with
irritable bowel syndrome
(
IBS
). Intraduodenal infusion of 100 ml of 0.1 N HCl or 10 g fat caused a significant rise in plasma VIP level. Neostigmine (12.5 micrograms/kg) produced a significant rise in plasma VIP level, and the plasma VIP response to neostigmine was significantly greater in the
IBS
group than in the normal group. These results suggest that VIP might play a role in the pathophysiology of
IBS
.
...
PMID:Release of vasoactive intestinal peptide by intraduodenal infusion of HCl or fat and intramuscular injection of neostigmine in man. 401 6
Inflammatory bowel disease is a recurrent intestinal inflammatory disorder that in adults has been associated with changes in enteric nervous system neuropeptide expression. The aim of the present study was to determine whether similar changes were observed in paediatric Crohn's disease. The distribution of
vasoactive intestinal peptide (VIP)
and neuronal nitric oxide synthase (nNOS) was determined in colonic tissues from children with ileo-colonic (n=4) and colonic (n=3) Crohn's disease. The submucosal plexus of inflamed regions showed significant increase in density of VIP immunoreactive neurons (margin, 48% vs. inflamed tissue, 82% of HuC/D positive neurons). The density of submucosal plexus nNOS immunoreactive neurons was too low to be reliably quantified. Using the pan-neuronal marker HuC/D, no significant difference in numbers of HuC/D positive submucosal neurons was evident except where neurons were normalized to length of tissue (margins, 3.6+/-0.7 vs. inflamed tissue, 4.0+/-0.6 neurons/ganglia, p=0.33; margins, 2.7+/-0.4 vs. inflamed tissue, 5.7+/-1.2, neurons/mm, p=0.03). In the myenteric plexus, there was a significant increase in the percent of NOS neurons (38% vs. 82% of HuC/D positive neurons) while there was no significant difference in percent of VIP neurons (4% vs. 8%). No difference in number of HuC/D positive myenteric neurons among margin and inflamed tissues was observed (margin, 12.2+/-3.0 vs. inflamed tissue, 12.5+/-5.1 neurons/ganglia, p=0.50; margins 9.1+/-2.1 vs. inflamed tissue, 13.7+/-2.3 neurons/mm, p=0.11). These data demonstrate that inflammation is associated with a differential expression of VIP and nNOS neuronal subpopulations within the two major enteric plexi, likely due to phenotypic switch. Such changes might contribute to the pathogenesis of
IBD
and ongoing symptoms even in quiescent disease.
...
PMID:Differential responses of VIPergic and nitrergic neurons in paediatric patients with Crohn's disease. 1746 1
The aim of this study was to investigate the mechanism(s) of action of gastrointestinal hormones in the pathogenesis of
irritable bowel syndrome
(
IBS
), and the correlation between gastrointestinal hormones and psychological factors. Patients with
IBS
were divided into
IBS
with normal emotional state ratings and
IBS
in anxiety-depressive states groups. The two groups were then subdivided into
IBS
-constipation predominant (IBS-C) and
IBS
-diarrhea predominant (IBS-D) groups. Non-
IBS
patients with normal depression and anxiety ratings were recruited as controls. The serum concentrations of somatostatin (SS) and
vasoactive intestinal peptide (VIP)
were measured by radioimmunoassay, and the expression of SS and VIP in the colonic mucosa was detected by immunohistochemistry and radioimmunoassay. The anxiety-depression scores of patients with
IBS
were significantly different from those of the control group (P<0.05). The expression levels of SS and VIP in the serum and colonic mucosa of the patients with
IBS
were higher compared with those of the control group. Furthermore, the expression level of SS in the
IBS
-C group demonstrated a significantly larger increase than that in the
IBS
-D group (P<0.05); however, there was no significant difference in the expression of VIP between the
IBS
-C and
IBS
-D groups (P>0.05). In addition, the expression levels of SS and VIP in the
IBS
groups with normal emotional state ratings were notably different from those in the
IBS
groups in anxiety-depressive states (P<0.05). Anxiety-depressive states may lead to changes in the secretion of SS and VIP, and subsequently to changes in gastrointestinal motility and function.
...
PMID:Correlation between gastrointestinal hormones and anxiety-depressive states in irritable bowel syndrome. 2413 53